
Contemporary art collage of hand holding an arrow. Concept of success, opportunity, and growth. Modern design. Copy space. | Photo Credit: beast01
ensex Today, Nifty 50 | Stock Market Live Updates - Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 5th May 2026.
- May 5, 2026 06:35
MARKETS at Monday close
Nifty Pharma advances 0.9%, Laurus Labs and Gland Pharma are the top performers
Nifty Energy index snaps 2-session losing streak, gains 0.6%, led by Bharat Heavy Electricals and Calcutta Electric Supply Corp
Nifty Auto gains 0.5%, Eicher and Maruti led the index
Nifty FMCG advances 0.3%, Colgate and Emami led the index
Nifty PSU Bank loses 0.2%, dragged down by Indian Bank and Central Bank
Nifty IT, top sectoral loser, declines 0.9%, dragged by Coforge and TCS
Nifty 50 advances 0.5%, closes below the 24,120 mark
Top Performers: Adani Ports and Jio Financial
Worst Performers: Bharti and Kotak Mahindra Bank
Nifty Bank closes flat
Nifty midcap and Nifty smallcap close in green, advance over 0.7%
Except for PSU bank and IT, all sectoral indices closes in green
Nifty Realty advances 2.5%, Anant Raj and Godrej Properties are the top gainers
Nifty Metal gains 1%, led by Vedanta and Jindal Steel
- May 5, 2026 06:35
ACUTAAS CHEMICALS – CONCALL HIGHLIGHTS
Battery Chemicals Expansion
- Phase1 capex completed at Jhagadia
- 2000MT capacity for VC and FEC
- Fully tied with 3-year contracts
- Production already commenced
- Revenue ramp through FY27
- Phase2 capex by Q1FY27
- Third product capex ongoing
- Two new products planned FY27
CDMO Pipeline
- 4 products validated commercially
- Under regulatory approval stage
- ₹50–100Cr peak revenue each
- Ramp-up expected by FY28
- 10-year supply contract secured
- Strong global client relationship
Growth Outlook
- FY27 revenue growth ~25%
- Consistent decade-long track record
- Three growth engines driving business
- Pharma CDMO largest contributor
- Battery chemicals ramping up
- Semiconductor recovery underway
Margins & Capex
- EBITDA margin ~34.5–35%
- FY27 capex ~₹90Cr planned
- Includes spillover and maintenance
- R&D expansion under consideration
R&D Expansion
- 10x capacity expansion planned
- Multi-sector R&D capabilities
- Pharma, battery, semiconductor focus
- Long-term innovation pipeline
Management Commentary
- Battery and semi become key engines
- Independent growth by FY28 expected
- CDMO ramp steep post commercialization
- Sustained growth visibility
Final Takeaway
- Strong multi-engine growth model
- High-margin specialty chemicals focus
- Execution key for next phase
Disclaimer
- Not a buy/sell recommendation
- May 5, 2026 06:34
Insights: Know 5 governance traps that destroy investor wealth
- May 5, 2026 06:33
Natural gas futures: Retain the short position
- May 5, 2026 06:32
Trading Guide for May 5, 2026: Intraday supports, resistances for Nifty50 stocks
- May 5, 2026 06:32
Stock to buy today: Laurus Labs (₹1,166.50)
Published on May 5, 2026






























